Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 16, Issue 8, 2012, Pages 1478-1486

  Peng, Peter ^a   Hyder, Omar ^a   Firoozmand, Amin ^a   Kneuertz, Peter ^a   Schulick, Richard D ^a   Huang, Donghang ^a   Makary, Martin ^a   Hirose, Kenzo ^a   Edil, Barish ^a   Choti, Michael A ^a   Herman, Joseph ^a   Cameron, John L ^a   Wolfgang, Christopher L ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Morbidity; Mortality; Outcomes; Pancreas surgery; Sarcopenia

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; EVALUATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MUSCLE ATROPHY; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PREOPERATIVE CARE; PSOAS MUSCLE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PREOPERATIVE CARE; PSOAS MUSCLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SARCOPENIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84864083215     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1923-5     Document Type: Article

References (41)

1. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1): 10-5.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6): 567-79.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297(3): 267-77.
4. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101(6): 908-15.
5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230(6): 776-82; discussion 82-4.
6. Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005; 92(5): 547-56.
7. Balzano G, Zerbi A, Capretti G, Rocchetti S, Capitanio V, Di Carlo V. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg 2008; 95(3): 357-62.
8. Balcom JHt, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136(4): 391-8.
9. Pratt W, Joseph S, Callery MP, Vollmer CM, Jr. POSSUM accurately predicts morbidity for pancreatic resection. Surgery 2008; 143(1): 8-19.
10. Emick DM, Riall TS, Cameron JL, et al. Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg 2006; 10(9): 1243-52; discussion 52-3.
11. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM, Jr. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 2007; 245(3): 443-51.
12. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141(5): 610-8.
13. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Annals of surgical oncology 2008; 15(1): 165-74.
14. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract 2009; 13(4): 752-9.
15. Deyle S, Banz VM, Wagner M, et al. Estimation of physiologic ability and surgical stress score does not predict immediate outcome after pancreatic surgery. Pancreas; 40(5): 723-9.
16. Hashimoto D, Takamori H, Sakamoto Y, Tanaka H, Hirota M, Baba H. Can the physiologic ability and surgical stress (E-PASS) scoring system predict operative morbidity after distal pancreatectomy? Surg Today; 40(7): 632-7.
17. Hashimoto D, Takamori H, Sakamoto Y, et al. Is an estimation of physiologic ability and surgical stress able to predict operative morbidity after pancreaticoduodenectomy? J Hepatobiliary Pancreat Sci; 17(2): 132-8.
18. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg; 210(6): 901-8.
19. Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford); 13(7): 439-46.
20. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009; 3(4): 269-75.
21. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15(8): 2920-6.
22. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol; 28(2): 340-7.
23. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol; 21(8): 1594-8.
24. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol; 28(6): 1054-60.
25. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15(22): 6973-9.
26. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma. Ann Surg Oncol; 18(13): 3579-85.
27. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg; 211(2): 271-8.
28. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250(2): 187-96.
29. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147(8): 755-63.
30. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004; 97(6): 2333-8.
31. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33(5): 997-1006.
32. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. The British journal of surgery 2012.
33. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annual review of medicine 2011; 62: 265-79.
34. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American journal of clinical nutrition 2006; 83(6): 1345-50.
35. Blum D, Omlin A, Fearon K, et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer; 18(3): 273-9.
36. Ockenga J, Valentini L. Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol Ther 2005; 22(7): 583-94.
37. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103(10): 2189-98.
38. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006; 61(10): 1059-64.
39. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32(11): 1993-7.
40. Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 2007; 30(6): 1507-12.
41. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. The American journal of clinical nutrition 2010; 91(4): 1133S-37S.